Opinion
Video
Author(s):
The panel provides comprehensive insights on approaching first-line treatment of patients with HER2+ metastatic breast cancer and the role of neratinib.
Video content above is prompted by the following question:
FDA Grants Fast Track Designation to HP518 for AR+ TNBC
Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing
Boosting ‘Natural Killer’ Cell Activity Could Improve Cancer Therapy
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors
Murthy Highlights Second-Line Treatment Considerations in ER+/HER2– Metastatic Breast Cancer
De-Escalation Strategies, Biomarkers Could Refine Treatment Algorithm for Early-Stage HER2+ Breast Cancer
Dr Feldman on New Approaches for Decreasing the Risk of Breast Cancer–Related Lymphedema
Dr Mukhtar on Challenges in the Diagnosis and Management of Invasive Lobular Carcinoma
Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast Cancer